

## Factsheet

|                 |  |
|-----------------|--|
| acronym         | KATY   |
| full title      | Knowledge At the Tip of Your fingers: Clinical Knowledge for Humanity  |
| programme       | Horizon 2020/H2020-SCI-FA-DTS-2020-1   |
| contract number | 101017453  |
| abstract        | <p>AI-empowered Personalized Medicine promises to find tailored, targeted, nearly “hand-made” cures for patients. Cancer treatment desperately needs boosters to find tailored, targeted cures for patients and Personalized Medicine can play a crucial role. Tailored, targeted therapies in cancer treatment are already a reality but the current practice of targeted therapies in cancer treatment has been derived with traditional methods of data analysis. AI-empowered Personalized Medicine may help to bring targeted therapies to the next level. However, no matter how precise it is, no matter how many lives it can save in principle, and no matter if it can utilize the entire medical knowledge. If clinicians do not understand its suggestions and decisions, AI-empowered Personalized Medicine will not be a game changer, clinicians will not use it to make everyday decisions and, thus, it is doomed to fail. Hence, the real challenge is building AI-empowered Personalized Medicine systems that can be accepted by clinicians and clinical researchers. In KATY, we grasp the above challenge and we propose an AI-empowered Personalized Medicine system that can bring medical “AI-empowered knowledge” to the tips of the fingers of clinicians and clinical researchers. The AI-empowered knowledge is a human interpretable knowledge that clinicians and clinical researchers can: understand, trust and effectively use in their everyday working routine. KATY is then a AI-empowered Personalized Medicine system built around two main components: A Distributed Knowledge Graph and A pool of eXplainable Artificial Intelligence predictors. As a stress test and due to the lack of personalized clinical responses, KATY will be experimented in a low prevalence and complex cancer: Clear cell renal cell carcinoma (ccRCC).</p> |
| duration        | 54 months (01/01/2021 – 30/06/2025)  |
| project funding | 8,479,900.00 €   |



coordinator Prof. Fabio Massimo Zanzotto  
Università degli Studi di Roma Tor Vergata  
Rome, Italy  
Email: [fabio.massimo.zanzotto@uniroma2.it](mailto:fabio.massimo.zanzotto@uniroma2.it)

- partners
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives, France
  - FCiências.ID – Associação para a Investigação e Desenvolvimento de Ciências, Portugal
  - The University of Edinburgh, United Kingdom
  - DS Tech Srl, Italy
  - Uniwersytet Gdański, Poland
  - The University Court of the University of St Andrews, United Kingdom
  - Universität Wien, Austria
  - Fundació Eurecat, Spain
  - EURICE - European Research and Project Office GmbH, Germany
  - Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
  - Universidad de Zaragoza, Spain
  - Personal Genomics Srl, Italy
  - Centre Hospitalier Universitaire de Grenoble, France
  - Lunds Universitet, Sweden
  - The Health Policy Institute, Greece
  - Ethniko Kai Kapodistriako Panepistimio Athinon, Greece
  - National Technical University of Ukraine Igor Sikorsky Kyiv Polytechnic Institute, Ukraine
  - Caretronic doo, Slovenia
  - PredictBy Research & Consulting SL, Spain

contact at eurice Sandra Türk  
Project Manager  
Alt-Reinickendorf 25  
13407 Berlin, Germany  
Phone: +49 30374415844  
Email: [s.tuerk@eurice.eu](mailto:s.tuerk@eurice.eu)

Website <https://katy-project.eu/>

